Myeloid-derived Suppressor Cell (MDSC) Immunophenotyping Service

The accurate identification and quantification of MDSC subsets are foundational to understanding their roles in disease. Our service utilizes advanced multi-parameter flow cytometry, allowing for the precise discernment of MDSC populations based on their distinct surface and intracellular marker expression.

• Key Subsets and Defining Markers: Creative Biolabs' assays are optimized for the precise identification of the two major MDSC subsets:
  • Monocytic MDSCs (M-MDSCs): In human samples, these are typically characterized by a Lineage (CD3/CD19/CD56/CD123)−CD11b+CD14+CD33+CD15−HLA-DRlow/− phenotype. In murine models, M-MDSCs are identified as CD11b+Ly6G−Ly6Chi. These cells represent a differentiation stage distinct from mature monocytes, possessing a unique immunosuppressive capacity.
  • Polymorphonuclear MDSCs (PMN-MDSCs): In humans, PMN-MDSCs are commonly defined by the expression of CD11b+CD14−CD15+ or CD11b+CD14−CD66b+. Their murine counterparts are identified as CD11b+Ly6G+Ly6Clo. Creative Biolabs differentiates these cells from conventional neutrophils through additional markers and morphological considerations, acknowledging their altered buoyancy and expression profiles.
• Emerging Markers and Advanced Gating Strategies: We integrate established and emerging markers to refine MDSC characterization. For instance, LOX-1 (lectin-type oxidized LDL receptor-1) has been established as a specific marker for human PMN-MDSCs, and CD84 has been suggested for both PMN-MDSCs and M-MDSCs. Our dedicated FACS teams apply sophisticated, multi-step gating strategies to accurately delineate MDSC populations, minimizing contamination from other myeloid cell types and ensuring high purity.
• Early-Stage MDSCs (eMDSCs): Creative Biolabs also offers characterization of immature, early-stage MDSCs (eMDSCs), typically defined as Lin−HLA-DR−CD33+ in humans. These cells represent a progenitor population that can further differentiate into PMN-MDSC or M-MDSC subsets under pathological conditions.
• Sample Versatility: Our robust protocols are adaptable to a wide array of biological samples, including whole blood, peripheral blood mononuclear cells (PBMCs), bone marrow, and various tissue types (e.g., tumor tissue). We employ meticulous sample handling techniques to preserve cell integrity and viability, particularly for sensitive PMN-MDSC populations which are prone to loss upon freezing.
• Addressing Analytical Challenges: While no single marker uniquely distinguishes MDSCs from mature myeloid cells, Creative Biolabs employs a multi-marker approach combined with advanced functional testing to overcome this limitation. For example, for PMN-MDSC enrichment, we utilize density gradient centrifugation followed by phenotypic and functional validation.

Beyond mere enumeration, the definitive characteristic of MDSCs is their immune-suppressive function. Creative Biolabs offers comprehensive functional assays to quantitatively assess this critical activity.

• T Cell Suppression Assays: The Gold Standard: Our primary functional readout is the MDSCs' ability to suppress T cell proliferation and function, considered the "gold standard" for MDSC assessment.
  • Co-culture Assays: Isolated MDSCs are co-cultured with target immune cells, typically CFSE-labeled T cells (autologous MDSC-depleted PBMCs from patients or homologous PBMCs from healthy controls), at titrated ratios. This allows for precise measurement of their inhibitory effect on T cell proliferation (via CFSE dilution) and cytokine production (e.g., IFN-γ).
  • Antigen-Specific vs. Non-Specific Stimulation: Creative Biolabs offers both antigen-specific (e.g., using cognate peptides or allogeneic mixed leukocyte reactions (MLR)) and non-specific (e.g., anti-CD3/CD28 antibody stimulation or lectins like PHA) T cell activation methods, with antigen-specific assays often preferred for their physiological relevance. For human MDSCs, a three-way allogeneic MLR is a reliable and frequently employed method.
• Measurement of Suppressive Mediators: We quantify the expression and activity of key immunosuppressive molecules produced by MDSCs, providing mechanistic insights into their suppressive functions. These include:
  • Arginase-1 (ARG1) and Inducible Nitric Oxide Synthase (iNOS/NOS2): Critical enzymes in arginine metabolism that deplete L-arginine, crucial for T cell activation. We assess their expression (e.g., via RT-PCR) and, where possible, downstream metabolites (e.g., ornithine, urea, NO).
  • Transforming Growth Factor-β (TGF-β) and Prostaglandin E2 (PGE2): Immunosuppressive cytokines and lipid mediators. We measure their levels in co-culture supernatants or serum using highly sensitive ELISA assays. As demonstrated in studies of COVID-19, elevated serum TGF-β is strongly associated with disease severity, underscoring its relevance as a mediator of MDSC activity.
• Rigorous Controls and Isolation Strategies: Creative Biolabs emphasizes the use of appropriate control groups (e.g., phenotypically similar cells from healthy donors or naive mice) to accurately attribute suppressive effects to MDSCs. We prioritize negative selection approaches for MDSC isolation whenever feasible to minimize potential functional alterations caused by antibody binding.

Creative Biolabs' service extends to the molecular characterization of MDSCs, providing crucial evidence for their distinct "pathologically activated" state compared to classically activated myeloid cells. This activation stems from chronic low-strength signals from pathological environments (e.g., tumors, chronic inflammation), leading to impaired phagocytosis, high reactive species production, and an anti-inflammatory cytokine profile.

• Molecular Signatures: We assess molecular parameters associated with MDSC immune suppression, including:
  • Transcription Factors and Apoptosis Regulators: Identifying specific transcription factor profiles that govern MDSC differentiation and survival.
  • Cytokine and Chemokine Receptor Signatures: Analyzing the expression of pro- and anti-inflammatory cytokines produced by MDSCs (e.g., IL-10, IL-6, TNF-α) and chemokine receptors influencing their trafficking.
  • Enzymes and Metabolic Pathways: Detailed analysis of ARG1, NOS2/iNOS, and components of the NADPH oxidase complex, along with their downstream metabolites, which are central to MDSC function.
  • Immune Checkpoint Ligands: Evaluation of checkpoint ligands such as PD-L1 on MDSCs, which can contribute to immune evasion, particularly in cancer.
• Integration with Clinical Context: Creative Biolabs' comprehensive molecular profiling provides deeper insights into MDSC biology, enabling researchers to correlate specific molecular characteristics with disease progression, therapeutic response, and patient outcomes.